title: Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.
authors.affiliation: Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. d.buurman@umcg.nl.
authors.forename: D J
authors.initials: DJ
authors.lastname: Buurman
authors.affiliation: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Maurer
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Keizer
authors.affiliation: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.|Department of Pharmacy, Section Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands.
authors.forename: J G W
authors.initials: JG
authors.lastname: Kosterink
authors.affiliation: Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Dijkstra
mesh_terms: D005260:Female; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male
chemical_list: D005765:Gastrointestinal Agents; D000069285:Infliximab